Asahi Kasei Corporation (AHKSF)
| Market Cap | 14.24B +38.6% |
| Revenue (ttm) | 19.46B +4.0% |
| Net Income | 1.19B +59.9% |
| EPS | 0.87 +61.6% |
| Shares Out | n/a |
| PE Ratio | 12.00 |
| Forward PE | n/a |
| Dividend | 0.28 (2.83%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 143 |
| Open | 9.81 |
| Previous Close | n/a |
| Day's Range | 9.81 - 9.81 |
| 52-Week Range | 7.46 - 11.84 |
| Beta | 0.65 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About Asahi Kasei
Asahi Kasei Corporation engages in material, homes, and healthcare businesses in Japan, the United States, China, and internationally. The company offers Pimel, a photosensitive PI material applied for semiconductor applications, such as buffer coating, passivation layers, and dielectric layers; Sunfort, a dry film photoresist; Novacure, a latent curing agent for epoxy resin; glass fabric for printed circuit boards; plastic optical fiber; sensors and devices; artificial suede products under the Dinamica name; Microza UF and MF industrial membra... [Read more]
Financial Performance
In fiscal year 2026, Asahi Kasei's revenue was 3.07 trillion, an increase of 1.22% compared to the previous year's 3.04 trillion. Earnings were 158.79 billion, an increase of 17.63%.
Financial numbers in JPY Financial StatementsNews
Asahi Kasei Enters First License Agreement for Production and Sale of Acetolyte™ Novel Electrolyte in China
TOKYO--(BUSINESS WIRE)--HighChem Shanghai to produce Acetolyte™ for sale to battery manufacturers in China.
Q1 2027 Asahi Kasei Corp Earnings Presentation (Japanese) Transcript
Q1 2027 Asahi Kasei Corp Earnings Presentation (Japanese) Transcript
Asahi Kasei Quarterly report: Q1 2027
Asahi Kasei has published its Q1 2027 quarterly earnings report on July 30, 2026.
Asahi Kasei Slides: Q1 2027
Asahi Kasei has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 30, 2026.
Asahi Kasei Microdevices Begins Mass Production of Camera‑less Modules for Detection of Falls, Vital Signs, Posture, and Position
TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices began mass production of the AK5816AIM, an AiM mmWave radar module.
Asahi Kasei's Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time
TOKYO--(BUSINESS WIRE)--Peptistar has integrated Asahi Kasei's novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of APIs.
EAS Batteries Starts Sales of Ultra-High-Power Cell Using Asahi Kasei's Novel Electrolyte Acetolyte™
DUSSELDORF, Germany--(BUSINESS WIRE)--EAS Batteries has commercialized its ultra-high-power lithium-ion LFP cell which incorporates Asahi Kasei's novel Acetolyte™.
Asahi Kasei Life Science Acquires License for Novel Antibody-Drug Conjugate Technology from The Noguchi Institute – A Major Milestone for More Efficient and Safer Cancer Treatments
TOKYO--(BUSINESS WIRE)--Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute.
Asahi Kasei Develops Novel Photosensitive Polyimide Film for Advanced Panel-Level Semiconductor Packaging
TOKYO--(BUSINESS WIRE)--Asahi Kasei has combined the features of its photosensitive polyimide (PSPI) and dry film photoresist (DFR) into a new photosensitive film.
Asahi Kasei Microdevices Debuts AK491x Premium Audio Op Amps at HIGH END Vienna 2026
TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices (AKM) has unveiled the AK491x series of premium audio operational amplifiers (op amps).
Asahi Kasei Optimizes Material Portfolio Through Supply Realignment by FY2030
TOKYO--(BUSINESS WIRE)--Asahi Kasei, a diversified global company, has announced plans to streamline operations at its Mizushima Works by fiscal 2030.
Asahi Kasei Slides: Q4 2026
Asahi Kasei has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 11, 2026.
Asahi Kasei Quarterly report: Q4 2026
Asahi Kasei has published its Q4 2026 quarterly earnings report on May 11, 2026.
Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy
TOKYO--(BUSINESS WIRE)--Asahi Kasei has announced the successful completion of its acquisition of Aicuris Anti-infective Cures AG (Aicuris).
Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases
TOKYO--(BUSINESS WIRE)--Asahi Kasei announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound.
Asahi Kasei Slides: Corporate presentation
Asahi Kasei has posted slides in relation to its latest quarterly earnings report, which was published on April 15, 2026.
Asahi Kasei Slides: Investor presentation
Asahi Kasei has posted slides in relation to its latest quarterly earnings report, which was published on April 15, 2026.
Chevron Technology Ventures, Asahi Kasei Invest in Heavy-Industry Robotics Company KEWAZO
MUNICH & HOUSTON--(BUSINESS WIRE)--KEWAZO, the robotics company transforming heavy industry worldwide, today announced a new funding round backed by Chevron Technology Ventures, Asahi Kasei, Benson Ca...
Asahi Kasei Begins Installation of Containerized Alkaline-Water Electrolyzer at Finland's First Commercial Hydrogen Refueling Station
TOKYO--(BUSINESS WIRE)--Asahi Kasei has started the installation of an Aqualyzer™-C3 at Finland's first commercial hydrogen refueling station in Jyväskylä.
Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris
CHELMSFORD, Mass. & TOKYO--(BUSINESS WIRE)--Asahi Kasei announced it has entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG.
Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases
Wuppertal, Germany, February 26, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that it has entered into a definitive agreement under which Asahi Kasei, through its wholly owned U...
Asahi Kasei Slides: Acquisition presentation
Asahi Kasei has posted slides in relation to its latest quarterly earnings report, which was published on February 26, 2026.
Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds
TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma announced an exclusive global license agreement regarding novel lead compounds for a single target with Alchemedicine.
Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases
TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma in collaboration with Alchemedicine has announced that AK1960 has advanced to a Phase I clinical study.
Asahi Kasei Quarterly report: Q3 2026
Asahi Kasei has published its Q3 2026 quarterly earnings report on February 3, 2026.